Next results · Q4 2026Projected
Jan 28, after the close
Thu, Jan 28, 2027in 81 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ended Oct 31, 2026
- 10-K window
- Jan 26 – Feb 4
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $2.15M
- Revenue, change from a year earlier: Q3 2026 +19.0%, Q2 2026 +11.8%, Q1 2026 −7.1%, Q4 2025 −7.9%
- Net income
- -$102.00
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 +144.3%, Q1 2026 +285.0%, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 +150.0%, Q1 2026 n/m, Q3 2025 n/m
Results day
Typical moveA typical move of 13.7% either way
Up after 1 of 9, down after 6.
The stock’s move from the last close before each release to the first close after it, over the last 9 releases. Largest: −96.9% after Q3 2010.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Monday
- 5 of its last 8
- Session
- after the close
- After quarter end
- 45 to 90 days
- 10-Q filed
- 45 to 47 days
- over its last 8
- 10-K filed
- 90 to 93 days
- over its last 8
Based on 8 prior 10-K filings.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR